EMA Authorised: Tibsovo (Ivosidenib) — Les Laboratoires Servier

View source ↗

Summary

The European Medicines Agency authorised Tibsovo (ivosidenib) for acute myeloid leukemia and cholangiocarcinoma in the EU, with Les Laboratoires Servier as the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Cholangiocarcinoma

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute;Cholangiocarcinoma. MAH: Les Laboratoires Servier. Decision date: 24/02/2026. Orphan medicine